Recent 8-K filings for KEQU

• August 27, 2026, 7:58 AM ET other materiality 0.15 neutral item 5.07

  Kewaunee shareholders re-elect three Class I directors, ratify auditors, approve exec comp

  Thomas D. Hull III re-elected with 1,623,693 for, 1,062 withheld; David S. Rhind 1,464,432 for, 160,323 withheld; John D. Russell 1,623,690 for, 1,065 withheld.

• August 26, 2026, 6:10 AM ET other materiality 0.10 neutral item 7.01item 9.01

  Kewaunee posts annual meeting investor deck; no financial results in filing

  Investor presentation and script posted to Investor Information section of kewaunee.com as Exhibits 99.1/99.2.

• August 25, 2026, 4:20 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Kewaunee to report Q1 FY2027 earnings on Sept 9, 2026

  Q1 FY2027 earnings release scheduled for Sept 9, 2026 after market close.

• June 23, 2026, 5:10 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Kewaunee Scientific reports FY2026 revenue up 17.3% to $282M; EPS down to $3.22 from $3.83

  Full-year sales $281.999M (+17.3% YoY); net earnings $9.618M vs $11.405M prior year.

• June 10, 2026, 4:07 PM ET other material materiality 0.15 neutral item 8.01item 9.01

  Kewaunee Scientific sets Q4 and FY2026 earnings release for June 23

  Results for quarter and fiscal year ended April 30, 2026 will be released after market close on June 23, 2026.

• March 11, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific Q3 sales +3.3% to $69.4M; diluted EPS $0.23 vs $0.45; backlog down 17% YoY

  Sales $69.4M (+3.3% YoY); pre-tax earnings $1.6M (+25.8%).

• February 25, 2026, 6:59 PM ET other material materiality 0.10 neutral item 8.01item 9.01

  Kewaunee Scientific sets Q3 FY2026 earnings release for March 11, 2026

  Earnings release scheduled for Wednesday, March 11, 2026 after market close.

• December 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Kewaunee Scientific Q2 FY2026: sales +46.8% to $70.1M, diluted EPS $0.82 vs $1.01

  Sales up 46.8% to $70.1M; net earnings $2.45M (-18.7%); diluted EPS $0.82 (vs $1.01).

• December 4, 2025, 6:59 PM ET debt materiality 0.70 positive item 1.01item 1.02item 2.03item 7.01item 9.01 ◈ Material Agreements ×2

  Kewaunee repays $23M seller notes early with new $10M term loan and revolver draw

  Entered First Amendment with PNC Bank for additional $10M term loan and revolver access to fund repayment.

• November 26, 2025, 6:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Kewaunee Scientific sets Q2 FY2026 earnings release for December 10, 2025

  Company will release Q2 fiscal 2026 results on December 10, 2025 after market close.

• September 11, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 5.03item 9.01 ◈ Governance Changes

  Kewaunee Scientific appoints J. Jette Campbell as Class II director; bylaws amended for board size

  J. Jette Campbell appointed to Board of Directors, effective Sept. 10, 2025; term expiring at 2027 annual meeting.

• September 10, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Kewaunee Scientific Q1 sales up 47%; EPS $1.04; backlog $205M; expects FY EBITDA increase

  Sales $71.1M (+46.9% YoY); diluted EPS $1.04 vs $0.74; net earnings $3.09M.

• August 29, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Kewaunee Scientific shareholders re-elect directors, ratify auditors, approve exec comp, set annual advisory vote

  Margaret B. Pyle and Donald F. Shaw were re-elected as Class III directors with 1,633,067 and 1,730,171 votes for, respectively.

• August 27, 2025, 7:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Kewaunee Scientific announces Q1 FY2026 earnings release date of Sept 10, 2025

  First quarter fiscal 2026 results to be released on Wednesday, September 10, 2025 after market close.

• August 27, 2025, 7:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  Kewaunee Scientific posts investor presentation for annual meeting

  Company posted investor presentation and script on its website under Investor Information.

• June 26, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Kewaunee Scientific Q4 sales up 36% to $77.1M; EPS $1.63, backlog $214.6M

  Q4 sales $77.1M, +36% YoY; pre-tax earnings $7.1M vs $1.3M prior year quarter (which included non-recurring pension charge).

• June 11, 2025, 7:59 PM ET other material materiality 0.20 neutral item 8.01item 9.01

  Kewaunee Scientific to report Q4 and FY2025 results on June 25, 2025

  Results for fourth quarter and fiscal year ended April 30, 2025 to be released June 25 after market close.

• March 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Kewaunee Q3 revenue +44% to $67.2M; adj. diluted EPS $1.09 vs $0.85

  GAAP diluted EPS $0.45 vs $0.85; net earnings $1.4M vs $2.5M; includes $2.5M Nu Aire acquisition & integration costs.

• March 12, 2025, 7:59 PM ET other material materiality 0.45 positive item 8.01item 9.01

  Kewaunee Scientific expands share repurchase authorization by 100,000 shares

  Board authorized repurchase of up to additional 100,000 shares under existing program; no expiration date.

• February 26, 2025, 6:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Kewaunee Scientific sets Q3 FY2025 earnings release for March 12, 2025

  Company will release Q3 FY2025 financial results after market close on Wednesday, March 12, 2025.

• January 16, 2025, 6:59 PM ET M&A materiality 0.75 positive item 9.01

  Kewaunee closes Nu Aire acquisition for $55M; audited Nu Aire FY24 net income $5.44M

  Kewaunee acquired Nu Aire for $55M on Nov 1, 2024, using $35M bank financing and $23M seller notes at 8%.

• December 11, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Kewaunee Scientific Q2 FY2025: Sales down 5.3%, diluted EPS $1.01 vs $0.93 YoY; backlog record $184.4M

  Net sales $47.8M (down 5.3% YoY); domestic sales up 6.5%, international down 30.1% due to India construction delays.

• November 27, 2024, 6:59 PM ET other materiality 0.15 neutral item 8.01item 9.01

  Kewaunee Scientific announces Q2 FY2025 earnings release date: Dec 11, 2024

  Earnings will be released after the close of trading on December 11, 2024.

• November 1, 2024, 7:59 PM ET M&A materiality 0.80 positive item 1.01item 2.01item 2.03item 7.01item 9.01 ◈ M&A Transactions

  Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line

  Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.

• September 11, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Kewaunee Scientific Q1 FY2025 sales down 2.9%, EPS $0.74 vs $0.86, backlog up 13%

  Sales $48.4M, down 2.9% YoY; diluted EPS $0.74 vs $0.86 in prior year quarter.

• August 29, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

  Kewaunee Scientific shareholders re-elect director, ratify auditor, approve say-on-pay

  Director Keith M. Gehl re-elected with ~1.4M votes for, 273K withheld, 740K non-votes.

• August 28, 2024, 7:59 PM ET other materiality 0.05 neutral item 8.01item 9.01

  Kewaunee Scientific to release Q1 FY2025 earnings on September 11, 2024

  Results will be reported after market close on Wednesday, September 11, 2024.

• August 28, 2024, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Kewaunee Scientific posts investor presentation for annual meeting; no material new info disclosed

  Company held virtual annual shareholder meeting on August 28, 2024.

• June 26, 2024, 7:59 PM ET earnings materiality 0.72 positive item 2.02item 9.01

  Kewaunee Q4 sales up 5%, adjusted EPS $1.55 vs $0.34; backlog rises to $155.6M

  Q4 sales $56.7M (+5% YoY); GAAP net earnings $11.0M (diluted EPS $3.71) include two non-recurring items.

• June 12, 2024, 7:59 PM ET other materiality 0.05 neutral item 8.01item 9.01

  Kewaunee Scientific schedules Q4/fiscal year 2024 earnings release for June 26

  No financial results or guidance provided in this filing; only the release date is announced.

• April 23, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01

  Kewaunee Scientific terminates pension plan, transfers $17.7M obligations via annuity

  Pension plan terminated effective April 30, 2024; $17.7M in obligations transferred via group annuity contracts.

• March 22, 2024, 7:59 PM ET leadership materiality 0.35 neutral item 5.02item 9.01

  CEO Thomas Hull III enters $250K retention bonus with 3-year clawback

  Retention bonus of $250,000 payable within 10 days of March 18, 2024 effective date.

• March 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Q3 FY2024 EPS $0.85 vs $0.25 YoY; net income triples despite 23% sales drop

  Sales $46.8M, down 23% YoY from $60.8M; net income $2.5M vs $0.7M.

• February 21, 2024, 6:59 PM ET other materiality 0.20 neutral item 8.01item 9.01

  Kewaunee Scientific to report Q3 FY2024 earnings on March 6, 2024 after market close

  Earnings release scheduled for Wednesday, March 6, 2024 after close of trading.

• December 6, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific swings to Q2 profit of $2.7M; EPS $0.93 vs -$0.09

  Sales $50.4M, down 7.6% YoY; net earnings $2.7M vs loss of $243K.

• November 15, 2023, 6:59 PM ET other materiality 0.15 neutral item 8.01item 9.01

  Kewaunee Scientific to release Q2 FY2024 earnings on Dec 6, 2023

  Q2 fiscal 2024 results scheduled for release on December 6, 2023 after market close.

• September 1, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific Q1 net earnings $2.47M vs loss of $0.75M YoY; EPS $0.86 vs ($0.27)

  Net earnings of $2.47M ($0.86 diluted EPS) vs net loss of $0.75M ($0.27 loss) in prior Q1.

• August 25, 2023, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×3

  Kewaunee shareholders approve 2023 Omnibus Incentive Plan with 374,633 new shares

  Plan authorizes 374,633 shares; approved by 1,419,893 for, 498,027 against.

• August 23, 2023, 7:59 PM ET other material materiality 0.10 neutral item 7.01item 9.01

  Kewaunee Scientific posts investor presentation for annual meeting; no material new information disclosed

  Investor presentation and script posted to company website and furnished as Exhibits 99.1 and 99.2.

• June 28, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific posts Q4 profit of $0.34/share; FY revenue up 30% to $219.5M

  Q4 net earnings $1,005,000 ($0.34 diluted EPS) vs net loss of $362,000 ($0.13 loss) in prior year.

• March 8, 2023, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Kewaunee Q3 net income $723K ($0.25 EPS) vs loss; sales up 49.7%

  Net earnings $723K ($0.25 diluted EPS) vs net loss $1,319K (-$0.47); sales $60.8M, +49.7% YoY.

• December 19, 2022, 6:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03 ◈ Debt Financings◈ Material Agreements

  Kewaunee Scientific enters $15M secured revolving credit facility with Mid Cap Funding IV Trust

  $15.0M initial revolving credit facility, expandable to $30.0M with lenders' consent.

• December 8, 2022, 6:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01 ◈ Earnings Releases

  Kewaunee Scientific Q2 sales up 39.8% to $54.6M; net loss narrows to $0.09/share from $1.11

  Sales $54.6M (+39.8% YoY); pre-tax earnings $456k vs loss $2.9M; net loss $243k vs $3.1M.

• September 8, 2022, 7:59 PM ET earnings materiality 0.60 positive item 2.02item 9.01

  Kewaunee Scientific Q1 FY2023 net loss narrows to $0.27/share; sales up 27% YoY

  Sales $50.1M, up 26.9% YoY from $39.5M; net loss of $747K vs $1.35M loss a year earlier.

• August 29, 2022, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Kewaunee Scientific re-elects directors Pyle and Shaw at 2022 annual meeting; FORVIS LLP ratified as auditor

  Margaret B. Pyle re-elected as Class III director with 1,656,879 votes for, 229,653 withheld.

• August 24, 2022, 7:59 PM ET other materiality 0.10 neutral item 7.01item 9.01

  Kewaunee posts investor presentation for annual meeting; no material financial details disclosed

  Company posted investor presentation and script to investor page on August 24, 2022.

• June 30, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Kewaunee Q4 sales up 28.4% to $49.7M; backlog record $173.9M; full year loss widens

  Q4 sales $49.7M (+28.4% YoY); pre-tax earnings $2.3M vs loss $0.95M; EBITDA $2.97M vs -$0.30M.

• June 6, 2022, 7:59 PM ET other material materiality 0.20 neutral item 4.01item 9.01

  Kewaunee Scientific changes auditor to FORVIS after DHG/BKD merger; no disagreements reported

  Kewaunee's auditor DHG merged with BKD on June 1, 2022; combined firm now operates as FORVIS LLP.

• June 2, 2022, 7:59 PM ET debt materiality 0.50 neutral item 1.01

  Kewaunee amends credit line: reduces to $3M, extends maturity to June 30, 2022

  Line of credit reduced from $4,715,823 to $3,000,000.

• May 27, 2022, 7:59 PM ET other material materiality 0.45 neutral item 8.01

  Kewaunee Scientific extends preferred equity purchase period by 30 days for CAI sale-leaseback

  Extended by 30 days the purchase period for preferred equity in CAI Investments Medical Products I Parent, LLC.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.45 · Most common event earnings

15 positive 1 negative 34 neutral

source · KEQU on sec.gov